Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.

ABSTRACT:

Background

Evidence on homologous recombination repair (HRR) mutation prevalence in prostate cancer (PC) patients and the diagnostic testing path to guide treatment remains limited outside of clinical trials. The objective of this study was to investigate the DNA source, type of tumor tissue, timing for testing in the patient's disease course, and rate of conclusive results in a real-world population.

Patients and methods

This was an observational, cohort study, involving 20 Italian cancer centers. The study population included consecutive PC patients undergoing germline, tumor, and/or plasma circulating tumor DNA (ctDNA) to profile HRR genes between January 1, 2020 and January 31, 2025.

Results

Among 1400 PC patients included, 248 (17.7%) showed (likely)pathogenic va

SUBMITTER: Incorvaia L 

PROVIDER: S-EPMC12921449 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature